(Q51983228)

19 April 2018

title

Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. (English)

1 reference

19 April 2018

author name string

Nathalie Etchart

1

1 reference

19 April 2018

Bas Baaten

2

1 reference

19 April 2018

Svein Rune Andersen

3

1 reference

19 April 2018

Lisa Hyland

4

1 reference

19 April 2018

Simon Y C Wong

5

1 reference

19 April 2018

Sam Hou

6

1 reference

19 April 2018

language of work or name

English

0 references

publication date

1 May 2006

1 reference

19 April 2018

European Journal of Immunology

published in

1 reference

19 April 2018

volume

36

1 reference

19 April 2018

issue

5

1 reference

19 April 2018

page(s)

1136-1144

1 reference

19 April 2018

Immunity to and frequency of reinfection with respiratory syncytial virus

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

Regulation of Toll-like receptor 4 expression in the lung following hemorrhagic shock and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

Generation of female genital tract antibody responses by local or central (common) mucosal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

The role of nasopharyngeal lymphoid tissue

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Distinct types of lung disease caused by functional subsets of antiviral T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Immunostimulating complexes (ISCOMs) for nasal vaccination

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

IgG antibody subclass responses determined by immunoblot in infants' sera following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Purification of human respiratory syncytial virus: superiority of sucrose gradient over percoll, renografin, and metrizamide gradients

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Isolation and characterization of mouse nasal-associated lymphoid tissue

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Use of Peyer's patch and lymph node fragment cultures to compare local immune responses to Morganella morganii

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535493

7 January 2021

Identifiers

DOI

10.1002/EJI.200535493

1 reference

19 April 2018

1 reference

19 April 2018